ELAN

Elanco Animal Health is transitioning from a leveraged consolidator to an innovative competitor, with new products driving EBITDA growth and market share gains. ELAN's innovation portfolio, including Zenrelia, Credelio Quattro, and Befrena, is capturing share in dermatology and parasiticide markets, challenging Zoetis' key franchises. Margin expansion and deleveraging are underway, supported by the Ascend program and strong cash flow; net leverage is targeted below 3.0x by 2027.

Vigilance and early intervention are key to minimizing animal injury and limiting the parasite's spread, according to Elanco's technical experts Emergency Use Authorization for Elanco's CLiK Extra provides livestock producers with a vital tool in the prevention of New World screwworm infestations. Elanco also offers producers Negasunt® Powder (coumaphos, propoxur, and sulfanilamide topical powder) and Tanidil®, which received emergency authorizations earlier this year, as well as EPA-registered Catron™ IV.

Elanco Animal Health President and CEO Jeff Simmons discusses what's behind the company's increased profit and revenue forecasts. Speaking on "Bloomberg The Close," Simmons also comments on the recent surge in tick bites and consumer spending on pet health products.

Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Addus HomeCare (ADUS) and Elanco Animal Health Incorporated (ELAN). But which of these two stocks offers value investors a better bang for their buck right now?

Elanco Animal Health Incorporated (ELAN) Q2 2026 Earnings Call Transcript

Although the revenue and EPS for Elanco Animal Health (ELAN) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Elanco Animal Health Incorporated (ELAN) came out with quarterly earnings of $0.34 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.26 per share a year ago.

Raising Full Year Outlook and Innovation Target, Improving Year-End Net Leverage Ratio Target Second Quarter 2026 Financial Results: Revenue of $1,368 million, an increase of 10% year-over-year; 8% organic constant currency growth Reported Net Income of $54 million, Adjusted Net Income of $174 million Adjusted EBITDA of $288 million; Adjusted EBITDA Margin of 21.2% Reported EPS of $0.11, Adjusted EPS of $0.34 Net leverage ratio of 3.1x Adjusted EBITDA Full Year 2026 Guidance: Raising innovation revenue target to $1.25 billion Raising revenue guidance to $5.09 billion to $5.14 billion, or 6% to 7% organic constant currency growth Raising Adjusted EBITDA to $1.01 billion to $1.035 billion, a year-over-year increase of 13% at midpoint Raising Adjusted EPS to $1.10 to $1.16, a year-over-year increase of 20% at midpoint Improving year-end net leverage ratio target to approximately 3.0x Adjusted EBITDA INDIANAPOLIS, Aug. 5, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today reported financial results for the second quarter of 2026, provided guidance for the third quarter of 2026, and updated guidance for the full year 2026. "Elanco's second quarter results demonstrate our momentum and leadership in the attractive animal health industry," stated Jeff Simmons, President and CEO of Elanco.

Report highlights Elanco's impact through innovation, expanded access to animal care, a stronger and more sustainable food system and investment in people and communities INDIANAPOLIS, July 31, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today released its 2025 Impact Report, "Leading with Purpose," highlighting how the company brings together purpose, innovation and business strategy to help address some of society's most pressing challenges. The report details Elanco's progress across four interconnected areas: going beyond for animals, customers, society and its people.

Elanco Animal Health (ELAN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.